Identify top producing clones with favorable product quality attributes for diverse protein therapeutics using Opto CLD
14 Sept 2026Developing complex protein therapeutics requires more than identifying the fastest-growing or highest-producing clones. Product quality and manufacturability must also be assessed early to avoid expanding unsuitable candidates through lengthy rounds of cell line development.
In this study, discover how Opto® Cell Line Development (CLD) enables high-throughput screening of individual clones using productivity and product quality measurements. Through workflows involving monoclonal antibodies and other protein formats, the study also demonstrates how early functional characterization can help identify promising clones from diverse populations.
Learn how combining clone selection with early product quality assessment can improve cloning efficiency, shorten development timelines and support the selection of manufacturable protein therapeutics.
Resource details:
Resource type: Application note
Page count: 12 pages
Read time: 18 mins
